vesicare mixtúra, dreifa 1 mg/ml
astellas pharma a/s* - solifenacinum súkkínat - mixtúra, dreifa - 1 mg/ml
vesicare filmuhúðuð tafla 5 mg
astellas pharma a/s* - solifenacinum súkkínat - filmuhúðuð tafla - 5 mg
vesicare filmuhúðuð tafla 10 mg
astellas pharma a/s* - solifenacinum súkkínat - filmuhúðuð tafla - 10 mg
omnipaque stungulyf, lausn 350 mg j/ml
ge healthcare as - iohexolum inn - stungulyf, lausn - 350 mg j/ml
omnipaque stungulyf, lausn 300 mg j/ml
ge healthcare as - iohexolum inn - stungulyf, lausn - 300 mg j/ml
omnipaque stungulyf, lausn 180 mg j/ml
ge healthcare as - iohexolum inn - stungulyf, lausn - 180 mg j/ml
omnipaque stungulyf, lausn 140 mg j/ml
ge healthcare as - iohexolum inn - stungulyf, lausn - 140 mg j/ml
resolor
takeda pharmaceuticals international ag ireland - prucalopride succinat - hægðatregða - Önnur lyf við hægðatregðu - resolor er ætlað til meðhöndlunar á langvarandi hægðatregðu hjá fullorðnum, þar sem hægðalyf geta ekki veitt fullnægjandi léttir.
adcetris
takeda pharma a/s - brentuximab vedotin - lymphoma, non-hodgkin; hodgkin disease - Æxlishemjandi lyf - hodgkin lymphomaadcetris is indicated for adult patients with previously untreated cd30+ stage iv hodgkin lymphoma (hl) in combination with doxorubicin, vinblastine and dacarbazine (avd). adcetris is indicated for the treatment of adult patients with cd30+ hl at increased risk of relapse or progression following autologous stem cell transplant (asct). adcetris is indicated for the treatment of adult patients with relapsed or refractory cd30+ hodgkin lymphoma (hl):following asct, orfollowing at least two prior therapies when asct or multi-agent chemotherapy is not a treatment option. systemic anaplastic large cell lymphomaadcetris in combination with cyclophosphamide, doxorubicin and prednisone (chp) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (salcl). adcetris is indicated for the treatment of adult patients with relapsed or refractory salcl. cutaneous t cell lymphomaadcetris is indicated for the treatment of adult patients with cd30+ cutaneous t cell lymphoma (ctcl) after at least 1 prior systemic therapy.
entyvio
takeda pharma a/s - vedolizumab - colitis, ulcerative; crohn disease - valdar ónæmisbælandi lyf - sárum colitisentyvio er ætlað fyrir meðferð fullorðinn sjúklinga með nokkuð að alvarlega virka sárum niðurgang sem hafa verið ófullnægjandi að bregðast við, misst að bregðast við, eða voru óþol að annaðhvort hefðbundin meðferð eða æxli drep þáttur alfa (tnfa) hemla. crohn-diseaseentyvio er ætlað fyrir meðferð fullorðinn sjúklinga með nokkuð að alvarlega virka crohn-sjúkdóm sem hafa verið ófullnægjandi að bregðast við, misst að bregðast við, eða voru óþol að annaðhvort hefðbundin meðferð eða æxli drep þáttur alfa (tnfa) hemla. pouchitisentyvio is indicated for the treatment of adult patients with moderately to severely active chronic pouchitis, who have undergone proctocolectomy and ileal pouch anal anastomosis for ulcerative colitis, and have had an inadequate response with or lost response to antibiotic therapy.